Pediatric Drug Development And Approval Standards Cases in D.C. Circuit

Browse 1 pediatric drug development and approval standards cases decided by D.C. Circuit. AI-powered summaries, holdings, and legal analysis.

1
Cases
1
Mixed

Pediatric Drug Development And Approval Standards Opinions from D.C. Circuit (1)

Vanda Pharmaceuticals, Inc. v. FDA

D.C. Circuit Reverses FDA's Rejection of Vanda's Hetlioz sNDA for Pediatric Use

D.C. Circuit · 2025-08-15 · Mixed · Impact: 65/100

Vanda Pharmaceuticals, Inc. v. FDA, decided by D.C. Circuit on August 15, 2025, resulted in a mixed outcome. The D.C. Circuit reviewed the FDA's refusal to approve Vanda Pharmaceuticals' supplemental ...

Frequently Asked Questions

Q: How many pediatric drug development and approval standards cases has D.C. Circuit decided?

CaseLawBrief currently tracks 1 pediatric drug development and approval standards cases from D.C. Circuit. This number is updated as new opinions are published.

Q: What types of outcomes occur in pediatric drug development and approval standards cases at D.C. Circuit?

Outcome breakdown: Mixed: 1.

Q: Where can I find plain English summaries of pediatric drug development and approval standards rulings from D.C. Circuit?

Each case page on CaseLawBrief includes an AI-generated plain English summary, key holdings, and legal analysis. Click any case above to read its full analysis.

Explore More

All D.C. Circuit Cases All Pediatric Drug Development And Approval Standards Cases All Courts All Topics Search